Related Experiment Video
Updated: Sep 20, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Tracking mutation and drug-driven alterations of oncokinase conformations
Andreas Feichtner1, Valentina Kugler1, Selina Schwaighofer1
1Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria.
This study introduces a novel kinase conformation (KinCon) biosensor for live-cell analysis of kinase activity. This tool aids in selecting effective cancer drugs tailored to specific patient mutations.
Area of Science:
- Cellular signaling and molecular biology
- Cancer biology and drug discovery
- Biotechnology and biosensor development
Background:
- Kinases are crucial in cellular signaling, acting as molecular switches.
- Altered kinase activity drives cancer development and metastasis.
- Targeting oncokinases is a key strategy in cancer drug discovery.
Purpose of the Study:
- To develop a cell-based reporter system for identifying effective lead molecules.
- To present the Kinase Conformation (KinCon) biosensor platform for live-cell kinase activity analysis.
- To facilitate patient-tailored drug discovery by assessing drug efficacy against specific kinase mutations.
Main Methods:
- Development of a modular KinCon biosensor platform for live-cell analysis.
- Recording kinase activity conformations of wild-type and mutated kinases upon drug exposure.
- Proof-of-principle studies profiling drug properties of BRAF and MEK1 kinases in intact cells.
Main Results:
- Demonstrated the KinCon biosensor's ability to analyze kinase activity states in live cells.
- Successfully profiled drug properties for BRAF and MEK1 kinases using the biosensor.
- Showcased the potential for systematic and patient-tailored drug discovery.
Conclusions:
- The KinCon biosensor platform enables live-cell assessment of kinase activity and drug responses.
- This technology supports personalized medicine by predicting drug efficacy for specific mutations.
- The biosensor concept offers new avenues for determining kinase inhibitor specificity and anticipating drug efficacy.
More Related Videos
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Treatment Resistant Cancers
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies
There are several types of targeted therapies against...